Evidence map›Paper›PMID 42908787›Full record

ArticleFrontiers in medicine2026

Development and internal validation of a nomogram-based screening tool for concurrent autoimmune hepatitis in children with intestinal diseases: a retrospective cohort study.

YanFang Hou

Abstract read
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

YanFang HouDepartment of Pediatric Ward One, Kaifeng Central Hospital, Kaifeng, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Autoimmune hepatitis (AIH) can complicate paediatric intestinal diseases, but practical tools for early screening and risk stratification are limited. Methods: This retrospective cohort study included 346 children with intestinal diseases treated at a tertiary centre from 2015 to 2023, including 68 with concurrent AIH and 278 without AIH. Baseline clinical and laboratory variables measured at the initial gastroenterology evaluation were analysed. Candidate variables were selected using least absolute shrinkage and selection operator logistic regression and entered into multivariable logistic regression to construct a nomogram-based screening model. Model performance was assessed using receiver operating characteristic curve analysis, calibration metrics, bootstrap internal validation, and decision curve analysis. Results: Eight variables associated with concurrent AIH were included: disease duration ≥12 months, C-reactive protein ≥15 mg/L, immunoglobulin G ≥16 g/L, erythrocyte sedimentation rate ≥25 mm/h, antinuclear antibody positivity, corticosteroid use, pancolitis, and family history of autoimmune disease. The model showed an apparent area under the curve (AUC) of 0.974 and a bootstrap-corrected AUC of 0.893. Calibration was acceptable, with a slope of 0.87, intercept of -0.03, Brier score of 0.098, and a non-significant Hosmer-Lemeshow test ( Conclusion: The nomogram may help screen children with intestinal diseases who warrant early hepatological evaluation for concurrent AIH. It should not be used as a standalone diagnostic instrument, and external validation is required before routine clinical use.

Indexed as

autoimmune hepatitischildrenintestinal diseasenomogramrisk stratificationscreening model

Identifiers

PMID42908787
PMCPMC13683181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.